CryoPortCYRX
CYRX
About: CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Employees: 1,186
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
10% more call options, than puts
Call options by funds: $2M | Put options by funds: $1.83M
3.88% less ownership
Funds ownership: 95.73% [Q4 2024] → 91.86% (-3.88%) [Q1 2025]
5% less funds holding
Funds holding: 160 [Q4 2024] → 152 (-8) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 55
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
24% less capital invested
Capital invested by funds: $368M [Q4 2024] → $279M (-$89.4M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
5%
upside
Avg. target
$10.80
62%
upside
High target
$15
125%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Needham David Saxon | 65%upside $11 | Buy Reiterated | 8 May 2025 |
Morgan Stanley Tejas Savant | 5%upside $7 | Equal-Weight Maintained | 5 May 2025 |
Guggenheim Subbu Nambi | 50%upside $10 | Buy Reiterated | 16 Apr 2025 |
Roth MKM Richard Baldry | 125%upside $15 | Buy Reiterated | 1 Apr 2025 |
UBS John Sourbeer | 65%upside $11 | Buy Maintained | 1 Apr 2025 |
Financial journalist opinion
Neutral
PRNewsWire
2 days ago
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
NASHVILLE, Tenn. , June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ("DHL"), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Believe CryoPort (CYRX) Could Rally 81.43%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 81.4% in CryoPort (CYRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect?
The mean of analysts' price targets for CryoPort (CYRX) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Seeking Alpha
1 month ago
Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP IR and Corporate Development Todd Fromer - IR, KCSA Strategic Communications Conference Call Participants Kyle Crews - UBS Richard Baldry - ROTH Capital David Larsen - BTIG Subbu Nambi - Guggenheim Securities Matt Stanton - Jefferies Anna Snopkowski - KeyBanc Operator Good afternoon, and welcome to Cryoport's First Quarter 2025 Earnings Call. All participants will start in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.43 per share a year ago.
Neutral
PRNewsWire
1 month ago
Cryoport Reports First Quarter 2025 Financial Results
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials as of March 31, 2025 Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025 NASHVILLE, Tenn. , May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.
Positive
Zacks Investment Research
1 month ago
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy?
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 month ago
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
NASHVILLE, Tenn. , April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close.
Neutral
Seeking Alpha
2 months ago
Cryoport, Inc. (CYRX) Strategic Agreement and Transaction with DHL Group Call (Transcript)
Cryoport, Inc. (NASDAQ:CYRX ) Strategic Agreement and Transaction with DHL Group Call March 31, 2025 8:30 AM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Tom Heinzen - Vice President, Corporate Development & Investor Relations Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Paul Knight - KeyBanc Tejas Savant - Morgan Stanley David Larsen - BTIG David Saxon - Needham Operator Good morning, and welcome to Cryoport's Investor Conference Call. All participants will start in a listen-only mode.
Neutral
PRNewsWire
2 months ago
DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.
Charts implemented using Lightweight Charts™